Headache medication and the COVID-19 pandemic

31Citations
Citations of this article
179Readers
Mendeley users who have this article in their library.

This artice is free to access.

Abstract

The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.

Cite

CITATION STYLE

APA

Maassenvandenbrink, A., De Vries, T., & Danser, A. H. J. (2020). Headache medication and the COVID-19 pandemic. Journal of Headache and Pain, 21(1). https://doi.org/10.1186/s10194-020-01106-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free